| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 07/05/2001 | WO2001047554A1 Stable antibody compositions and injection preparations |
| 07/05/2001 | WO2001047553A1 Micelle-forming lipopeptides targeted at antigen presenting cells useful as vaccine adjuvants |
| 07/05/2001 | WO2001047551A2 Eliciting antibodies specific for hepatitis c virus (hcv) |
| 07/05/2001 | WO2001047546A2 Methods and products for tumor immunotherapy using cytokines |
| 07/05/2001 | WO2001047542A1 Vancomycin preparations |
| 07/05/2001 | WO2001047539A1 Pharmaceutical composition for preventing and treating erectile impotence using purified sumsoo extract |
| 07/05/2001 | WO2001047532A1 System for stabilizing lacrimal fluid layer |
| 07/05/2001 | WO2001047526A1 Remedies for external use for allergic skin diseases |
| 07/05/2001 | WO2001047525A1 Antipruritic agents for external use |
| 07/05/2001 | WO2001047521A1 Use of ketotifen as ophthalmic agent |
| 07/05/2001 | WO2001047519A1 Powdery biotin preparations |
| 07/05/2001 | WO2001047503A1 Transdermal administration of reboxetine |
| 07/05/2001 | WO2001047502A1 Patch for transdermal therapy |
| 07/05/2001 | WO2001047501A1 Drug delivery system exhibiting permeability control |
| 07/05/2001 | WO2001047500A1 Hydrogel-driven drug dosage form |
| 07/05/2001 | WO2001047499A1 Pharmaceutical formulations comprising sodium amoxycillin and potassium clavulanate |
| 07/05/2001 | WO2001047498A2 Hydrogel-driven layered drug dosage form comprising sertraline |
| 07/05/2001 | WO2001047497A2 Controlled release pharmaceutical composition containing tramadol hydrochloride |
| 07/05/2001 | WO2001047496A1 Histidine copolymer and methods for using same |
| 07/05/2001 | WO2001047495A1 Pharmaceutical compositions providing enhanced drug concentrations |
| 07/05/2001 | WO2001047494A1 Method for co-grinding substances and lactose by means of jet mils |
| 07/05/2001 | WO2001047493A1 Pharmaceutical aerosol formulation of salmeterol and fluticasone propionate |
| 07/05/2001 | WO2001047492A1 Improved pharmaceutical compositions for poorly soluble drugs |
| 07/05/2001 | WO2001047491A1 Methods and formulations for the efficient delivery of water-insoluble drugs by nebulizer |
| 07/05/2001 | WO2001047490A1 Devices for the delivery of drugs having antiprogestinic properties |
| 07/05/2001 | WO2001040446A8 Pour-on formulations |
| 07/05/2001 | WO2001000654A3 Purification and stabilization of peptide and proteins in pharmaceutical agents |
| 07/05/2001 | WO2000078332A3 Fish serine proteinases and their pharmaceutical and cosmetic use |
| 07/05/2001 | WO2000074714A3 Indicators for monitoring the technique of transcutaneous immunization |
| 07/05/2001 | WO2000074650A3 Implantable gel compositions and method of manufacture |
| 07/05/2001 | WO2000066138A3 Metabolic intervention with glp-1 to improve the function of ischemic and reperfused tissue |
| 07/05/2001 | WO2000050050A8 Multiparticulate formulation |
| 07/05/2001 | US20010007025 Antisense modulation of bcl-x expression |
| 07/05/2001 | US20010006989 Pre-polymerization, monomer(s) dissolved in water-miscible aprotic organic solvent forming non-solvent mixture of polymer; prophylactic or curative antibiotics or antiseptic agents |
| 07/05/2001 | US20010006983 For delivery of biologically active agents; comprising Aloe vera polysaccharide, piperine, cyclic adenosine monophosphate (cAMP), calcium phosphate and glycyrrhizin; increases permeability of gastrointestinal epithelial cells |
| 07/05/2001 | US20010006968 Use of ophthalmic agent |
| 07/05/2001 | US20010006957 Microdispersed or microfibrillar polyanhydroglucuronic acids and salts, complex salts or intermolecular polymer complexes suitable for fixing drug dosages with significantly protracted effect and reduced toxicity |
| 07/05/2001 | US20010006944 Treating noninvasive fungus-induced rhinosinusitis by mucoadministering an antifungal agent; culturing noninvasive fungus from a mammalian mucus sample for antigen/antibody production; apparatus for collecting nasal mucus |
| 07/05/2001 | US20010006939 Secretory leukocyte protease inhibitor dry powder pharmaceutical compositions |
| 07/05/2001 | US20010006784 Apolipoprotein e polymorphism and treatment of alzheimer's disease |
| 07/05/2001 | US20010006698 Starch microcapsules for delivery of active agents |
| 07/05/2001 | US20010006679 X-ray crystallography reagent |
| 07/05/2001 | US20010006678 Sustained-release material prepared by dispersing a lyophilized polypeptide in an oil phase |
| 07/05/2001 | US20010006677 Effervescent controlled release water soluble or swellable hot-melt extruded films made form hot-melt extrudable water soluble binder, an active agent, and an effervescent couple; controlled release hot-melt extruded film |
| 07/05/2001 | US20010006675 Forming a formulation comprising protease enzyme and polyvinyl alcohol film forming agent, topically applying the formulation, incubating to form a film incorporating enzyme, removing the film incorporating the enzyme from the site |
| 07/05/2001 | US20010006671 Gel system for oral and topical administration of water insoluble and/or water intolerant drugs and supplements |
| 07/05/2001 | US20010006667 Use and composition of an anti-sexually transmitted diseases formulation |
| 07/05/2001 | US20010006662 A lipid regulating agent selected from a fibrate or statin dispersed or dissolved in a hydrophilic, amorphous polymer in which antilipidimic agent present as metastable, amorphous phase |
| 07/05/2001 | US20010006660 Low-rigidity liposomal formulation |
| 07/05/2001 | US20010006658 Lipid-regulating agent dissolved in one or more non-aqueous and/ or water-miscible solvents |
| 07/05/2001 | US20010006656 Comprising an aerosol formulation of a 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase inhibitor, said HMG-CoA reductase inhibitor being present at a concentration of less than 0.1 mg |
| 07/05/2001 | US20010006655 Process for preparing solid formulations of lipidregulating agents with enhanced dissolution and absorption |
| 07/05/2001 | US20010006650 Therapeutic agent dispersed in solid beadlet comprising at least 20% by weight of at least one hydrophobic long chain fatty acid or ester thereof and at least 3.0% by weight of at least one surfactant |
| 07/05/2001 | US20010006649 Stable oral pharmaceutical dosage forms |
| 07/05/2001 | US20010006648 Stability of drugs is improved by incorporating the drugs in liposomes which have a sphingolipid as the main component of the liposomal membrane-constituting lipids |
| 07/05/2001 | US20010006645 Method for transdermal drug delivery |
| 07/05/2001 | US20010006644 Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night |
| 07/05/2001 | US20010006643 Loading liposomes with solute without vesicular collapse by combining aqueous solution of liposomes with solute and solvent to increase membrane permeability of liposomes to solute, solute entering liposome by transmembrane permeation |
| 07/05/2001 | US20010006635 Decreasing localized inflammatory responses in a tissue of a patient by administering to said patient heparinase enzyme in an effective amount sufficient to decrease said localized inflammatory response |
| 07/05/2001 | US20010006634 Providing a bonding composition comprising isolated chondrocytes mixed with a biological gel, applying composition to a surface of first cartilage piece and contacting surface with second cartilage piece |
| 07/05/2001 | US20010006630 Biological material such as cell, and purified extracellular matrix degrading enzyme externally adhered thereto; for treating mucopolysaccharidoses, cystic fibrosis, parkinson's disease, Gaucher's syndrome and osteogeneis imperfecta |
| 07/05/2001 | US20010006628 Adhesive mixture for transdermal delivery of highly plasticizing drugs |
| 07/05/2001 | US20010006625 Comprising one or more glucocorticoids, physiologicall tolerable solvent(s), and water insoluble film-forming agents |
| 07/05/2001 | US20010006617 Formulations for therapeutic agents absorbed through mucous membranes |
| 07/05/2001 | US20010006616 Polymeric delivery of radionuclides and radiopharmaceuticals |
| 07/05/2001 | DE19963888A1 Medicinal mouth treatment device for babies and small children, comprises a comforter which is colored red and shaped as a bear, and is provided with a medicament with an acceptable taste |
| 07/05/2001 | DE19963538A1 Verwendung eines Enzyms zur Verbesserung der Geweberesorption von Arzneimitteln Use of an enzyme to improve tissue resorption of drugs |
| 07/05/2001 | DE19963319A1 Orale pharmazeutische Zubereitung An oral pharmaceutical preparation |
| 07/05/2001 | DE19960924A1 Amphiphile Polyamine, deren Anwendungen und Verfahren zu ihrer Synthese Amphiphilic polyamines, their applications and methods for their synthesis |
| 07/05/2001 | CA2396380A1 Improved pharmaceutical compositions for poorly soluble drugs |
| 07/05/2001 | CA2395993A1 Antidiabetic preparation for oral administration |
| 07/05/2001 | CA2395544A1 Method of achieving persistent transgene expression |
| 07/05/2001 | CA2395454A1 Viral core protein-cationic lipid-nucleic acid-delivery complexes |
| 07/05/2001 | CA2395362A1 Osmotic beneficial agent delivery system |
| 07/05/2001 | CA2395259A1 Substituted n-benzyl-indol-3-yl glyoxylic acid derivatives having an anti-tumoral effect |
| 07/05/2001 | CA2394758A1 Histidine-containing copolymers enhance pharmaceutical agent delivery |
| 07/05/2001 | CA2394393A1 Remedies for external use for allergic skin diseases |
| 07/05/2001 | CA2363180A1 Use of lithium (li+) for the preparation of a composition for transfection of a polynucleotide into a cell and compositions useful in gene therapy |
| 07/04/2001 | EP1112749A2 Preventives or remedies for eye circulatory failure |
| 07/04/2001 | EP1112740A1 Use of a water-soluble composition comprising polyglycerine |
| 07/04/2001 | EP1112739A1 Long time drug-sustained release preparation |
| 07/04/2001 | EP1112738A2 Stable extended release oral dosage composition comprising pseudoephedrine and desloratadine |
| 07/04/2001 | EP1112737A1 Oral pharmaceutical preparation comprising paracetamol and metoclopramide |
| 07/04/2001 | EP1112346A1 Utilization of nanocells in final culture medium products |
| 07/04/2001 | EP1112090A2 Method of stimulating prosaposin receptor activity |
| 07/04/2001 | EP1112089A1 Compositions comprising sympathomimetic amine salts unsuitable for illegal use |
| 07/04/2001 | EP1112082A2 Stable liquid formulations of botulinum toxin |
| 07/04/2001 | EP1112074A1 Taurolidine and/or taurultam against infectious ulcer or gastritis |
| 07/04/2001 | EP1112072A2 Methimazole derivatives and tautomeric cyclic thiones to treat autoimmune diseases |
| 07/04/2001 | EP1112066A2 Use of methoxymorpholino doxorubicin for the treatment of a liver tumor |
| 07/04/2001 | EP1112065A1 Pharmaceutical composition comprising entacapone or nitecapone as well as a cross-linked cellulose deivative |
| 07/04/2001 | EP1112064A1 Method for preparing novel fenofibrate galenic formulations, galenic formulations obtained and applications |
| 07/04/2001 | EP1112063A1 Lipstatin derivative-soluble fiber tablets |
| 07/04/2001 | EP1112062A1 Mousse composition |
| 07/04/2001 | EP1112061A1 Drug preparations for treating sexual dysfunction |
| 07/04/2001 | EP1112060A1 Dosage form comprising liquid formulation |
| 07/04/2001 | EP1112053A1 Organosilicone compositions for personal care |
| 07/04/2001 | EP1112052A1 Method and device for producing tablets |
| 07/04/2001 | EP1112005A1 Antioxidant composition comprising acetyl l-carnitine and alpha-lipoic acid |
| 07/04/2001 | EP0969832B1 Pharmaceutical composition for oral administration of a n-piperidino- 3-pyrazolecarboxamide derivative, its salts and their solvates |